Get the Stockscreener App
9.61
0.47%
0.04
Evolus Inc stock is traded at $9.61, with a volume of 51,596.
It is up +0.47% in the last 24 hours and up +2.51% over the past month.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
See More
Previous Close:
$9.57
Open:
$9.68
24h Volume:
51,596
Relative Volume:
0.05
Market Cap:
$619.61M
Revenue:
$202.09M
Net Income/Loss:
$-61.69M
P/E Ratio:
-8.8981
EPS:
-1.08
Net Cash Flow:
$-35.64M
1W Performance:
+4.51%
1M Performance:
+2.51%
6M Performance:
-31.42%
1Y Performance:
-23.63%
1-Day Range:
$9.52
$9.734
1-Week Range:
$9.1212
$9.734
52-Week Range:
$8.67
$17.82
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
9.61 | 597.69M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
152.38 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.745 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.59 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
300.97 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | BTIG Research | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
What analysts say about Evolus Inc. stockExtraordinary profit generation - Autocar Professional
Evolus to Report Second Quarter Financial Results on August 5, 2025 - BioSpace
Evolus Inc. Stock Analysis and ForecastDynamic investment opportunities - jammulinksnews.com
Is Evolus Inc. a good long term investmentFree Risk Assessment Services - Autocar Professional
What drives Evolus Inc. stock priceFree Predictions - Autocar Professional
EvolusA Slightly Risky Buy Ahead Of Q2 Earnings (NASDAQ:EOLS) - Seeking Alpha
Midday Stock Roundup: loanDepot Up 10% with High Volume - Orange County Business Journal
How Evolus Inc. stock performs during market volatilityInsider Level Guidance - Newser
What makes Evolus Inc. stock price move sharplyTop Analyst Picks - Newser
Why Evolus Inc. stock attracts strong analyst attentionRisk Controlled Trading Ideas - Newser
Evolus announces inducement grants - Medical Buyer
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 11, 2025 - BioSpace
How reliable are EOLS's earnings forecasts historically? - AInvest
Is EOLS's Q1 2025 earnings forecast optimistic? - AInvest
Evolus Expands into French Market - Orange County Business Journal
EOLS Partners with Symatese for Nuceiva Distribution in France | - GuruFocus
Fastest-Growing Botox Alternative Nuceiva Enters French Beauty Market Through Strategic Partnership - Stock Titan
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France - Yahoo Finance
Trade Alert: President Of Evolus David Moatazedi Has Sold Stock - simplywall.st
Where are the Opportunities in (EOLS) - news.stocktradersdaily.com
When Can We Expect A Profit From Evolus, Inc. (NASDAQ:EOLS)? - Yahoo Finance
Evolus (NASDAQ:EOLS) Shares Down 5.5% on Insider Selling - Defense World
(EOLS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | EOLS Stock News - GuruFocus
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Mizuho Securities Reaffirms Their Buy Rating on Evolus (EOLS) - The Globe and Mail
Evolus Inc (EOLS) Stock Price Up 3.95% on Jun 11 - GuruFocus
Insider Spends US$189k Buying More Shares In Evolus - simplywall.st
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):